MARKET

ACRV

ACRV

Acrivon Therapeutics, Inc.
NASDAQ
1.420
+0.010
+0.71%
After Hours: 1.440 +0.02 +1.41% 17:29 06/09 EDT
OPEN
1.430
PREV CLOSE
1.410
HIGH
1.480
LOW
1.375
VOLUME
246.80K
TURNOVER
--
52 WEEK HIGH
3.560
52 WEEK LOW
1.150
MARKET CAP
60.78M
P/E (TTM)
-0.7094
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRV last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at ACRV last week (0525-0529)?
Weekly Report · 06/01 10:17
Weekly Report: what happened at ACRV last week (0518-0522)?
Weekly Report · 05/25 10:20
Acrivon CEO joins TD Cowen Oncology Innovation Summit virtual fireside chat
PUBT · 05/21 11:31
Weekly Report: what happened at ACRV last week (0511-0515)?
Weekly Report · 05/18 10:20
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
TipRanks · 05/16 15:55
Acrivon grants employee stock options for 111,150 shares under inducement plan
PUBT · 05/15 20:00
ACRIVON THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/15 20:00
More
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Webull offers Acrivon Therapeutics Inc stock information, including NASDAQ: ACRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRV stock methods without spending real money on the virtual paper trading platform.